Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.16B |
| 2 |
Bank of America
BAC
|
+$855M |
| 3 |
Comcast
CMCSA
|
+$620M |
| 4 |
Amazon
AMZN
|
+$505M |
| 5 |
Micron Technology
MU
|
+$486M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Goldman Sachs
GS
|
+$441M |
| 2 |
Palo Alto Networks
PANW
|
+$300M |
| 3 |
Verizon
VZ
|
+$286M |
| 4 |
Fidelity National Information Services
FIS
|
+$285M |
| 5 |
Stanley Black & Decker
SWK
|
+$244M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Financials | 6.16% |
| 3 | Industrials | 5.09% |
| 4 | Consumer Discretionary | 4.89% |
| 5 | Healthcare | 4.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XLRN
2726
DELISTED
Acceleron Pharma
XLRN
| $3.6M | ﹤0.01% |
84,819
-152,693
| -64% | -$5.73M |
|
|
TTM
2727
PUT
DELISTED
Tata Motors Limited
TTM
| $3.6M | ﹤0.01% |
108,800
+59,700
| +122% | +$1.93M |
|
2728
CALL
Nabors Industries
NBR
$1.39B
| $3.6M | ﹤0.01% |
10,532
+180
| +2% | +$57.3K |
|
|
PPL
2729
CALL
PPL Corp
PPL
$27.1B
| $3.6M | ﹤0.01% |
116,200
+9,400
| +9% | +$338K |
|
2730
American Express
AXP
$231B
| $3.59M | ﹤0.01% |
36,168
-1,648,729
| -98% | -$157M |
|
2731
CALL
DexCom
DXCM
$33.9B
| $3.59M | ﹤0.01% |
250,000
-116,800
| -32% | -$1.52M |
|
2732
Plexus
PLXS
$7.13B
| $3.59M | ﹤0.01% |
59,063
+26,912
| +84% | +$1.63M |
|
|
TCO
2733
DELISTED
Taubman Centers Inc.
TCO
| $3.58M | ﹤0.01% |
54,749
+4,107
| +8% | +$226K |
|
2734
PUT
Zillow
Z
$7.82B
| $3.58M | ﹤0.01% |
87,500
-8,800
| -9% | -$362K |
|
2735
PUT
Invesco CurrencyShares Canadian Dollar Trust
FXC
$73.9M
| $3.58M | ﹤0.01% |
45,600
+4,200
| +10% | +$326K |
|
2736
Photronics
PLAB
$1.96B
| $3.58M | ﹤0.01% |
419,749
-80,424
| -16% | -$735K |
|
|
NXGN
2737
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $3.58M | ﹤0.01% |
263,389
-36,975
| -12% | -$531K |
|
2738
CALL
State Street SPDR S&P Bank ETF
KBE
$1.76B
| $3.57M | ﹤0.01% |
75,500
+14,400
| +24% | +$662K |
|
2739
PUT
Trade Desk
TTD
$6.64B
| $3.57M | ﹤0.01% |
781,000
+380,000
| +95% | +$2.1M |
|
2740
Movado Group
MOV
$803M
| $3.56M | ﹤0.01% |
110,719
+674
| +0.6% | +$19.5K |
|
2741
PUT
KKR & Co
KKR
$102B
| $3.56M | ﹤0.01% |
169,100
+94,100
| +125% | +$1.89M |
|
|
ZAYO
2742
CALL
DELISTED
Zayo Group Holdings, Inc.
ZAYO
| $3.56M | ﹤0.01% |
96,700
-12,100
| -11% | -$428K |
|
2743
Loews
L
$23.1B
| $3.56M | ﹤0.01% |
71,110
-192,507
| -73% | -$9.51M |
|
2744
Invesco Global Listed Private Equity ETF
PSP
$250M
| $3.56M | ﹤0.01% |
+57,150
| New | +$3.6M |
|
2745
TriMas Corp
TRS
$1.4B
| $3.56M | ﹤0.01% |
132,965
+23,853
| +22% | +$635K |
|
|
NVO
2746
PUT
Novo Nordisk
NVO
$201B
| $3.54M | ﹤0.01% |
131,800
+92,600
| +236% | +$2.35M |
|
2747
iShares Select Dividend ETF
DVY
$24.1B
| $3.54M | ﹤0.01% |
35,880
+17,613
| +96% | +$1.7M |
|
2748
SLR Investment Corp
SLRC
$703M
| $3.54M | ﹤0.01% |
174,961
+39,136
| +29% | +$833K |
|
|
HDV
2749
iShares Core High Dividend ETF
HDV
$15.1B
| $3.53M | ﹤0.01% |
196,020
+119,105
| +155% | +$2.08M |
|
2750
CALL
Energous
WATT
$86M
| $3.53M | ﹤0.01% |
303
+142
| +88% | +$893K |
|
Similar funds
Ken Griffin's Q4 2017 Portfolio in Review
As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.
- Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
- Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
- Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
- Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
- Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
- Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
- Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.
Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.